Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981952 · ClinicalTrials.gov registry record · Phase 1
Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine
A Phase 1 study of Risk Reduction, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT03981952 is a Phase 1 study of Risk Reduction that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 96 participants, below the 3,691-participant average among 13 other Risk Reduction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03981952, a Phase 1 study of Risk Reduction, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled dose-escalation study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)
- BIOLOGICAL Trivalent Invasive Salmonella Disease Vaccine (12 µg)
- BIOLOGICAL Trivalent Invasive Salmonella Disease Vaccine (25 µg)
- BIOLOGICAL Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)
Study Locations (1)
Maryland
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2021-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981952
The ClinicalTrials.gov registry entry for NCT03981952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,691-participant average among 13 other Risk Reduction trials with a reported enrollment target (97% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Risk Reduction appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03981952 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03981952 about?
NCT03981952 is a clinical study titled "Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine". This is a randomized, placebo-controlled dose-escalation study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
What is the current status of trial NCT03981952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2019-10-28. Estimated completion is 2021-05-07.
What conditions does trial NCT03981952 study?
This clinical trial studies the following conditions: Risk Reduction.
What interventions are being tested in trial NCT03981952?
The interventions under investigation include: Placebo (OTHER), Trivalent Invasive Salmonella Disease Vaccine (6.25 µg) (BIOLOGICAL), Trivalent Invasive Salmonella Disease Vaccine (12 µg) (BIOLOGICAL), Trivalent Invasive Salmonella Disease Vaccine (25 µg) (BIOLOGICAL), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03981952?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981952 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Risk Reduction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
RECRUITING
-
Blood Donor CVD 5000
RECRUITING · Phase 4
-
Tennessee Youth Prepared for Success
ACTIVE NOT RECRUITING · NA
-
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
ACTIVE NOT RECRUITING · Phase 2
-
PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men
COMPLETED · NA
-
Efficacy of Communication Modalities for Promoting Flu Shots
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.